Globe Newswire TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...\n more…
Ticker Report Avid Bioservices (NASDAQ:CDMO - Get Free Report) had its price objective upped by stock analysts at Royal Bank of Canada from $8.00 to $12.00 in a research report issued on Tuesday, Benzinga reports...\n more…
Ticker Report Avid Bioservices (NASDAQ:CDMO - Get Free Report) was upgraded by stock analysts at StockNews.com to a "sell" rating in a report released on Tuesday. Other research analysts have also issued reports...\n more…
Ticker Report Avid Bioservices (NASDAQ:CDMO - Get Free Report)s stock had its "market perform" rating reissued by stock analysts at William Blair in a report released on Tuesday, MarketBeat Ratings reports...\n more…
Ticker Report Avid Bioservices, Inc. (NASDAQ:CDMO - Get Free Report) shares gapped up prior to trading on Tuesday after StockNews.com upgraded the stock to a sell rating. The stock had previously closed at $8.95...\n more…